Article
Amgen today announced the appointment of Fred Hassan, partner and managing director of Warburg Pincus LLC, to the Amgen Board of Directors.
PRESS RELEASE
THOUSAND OAKS, Calif.
,
July 30, 2015
/PRNewswire/ --
Amgen
(NASDAQ: AMGN) today announced the appointment of
Fred Hassan
, partner and managing director of
Warburg Pincus LLC
, to the Amgen Board of Directors.
"We are pleased to welcome
Fred Hassan
and the deep, global experience he brings in the biopharmaceuticals sector to the Amgen Board," said
Robert A. Bradway
, chairman and chief executive officer of Amgen. "Fred's breadth of operational expertise and commitment to innovation will serve
Amgen
well."
Mr. Hassan has been Partner and Managing Director at
Warburg Pincus LLC
, a global private equity investment institution, since 2011 and, prior to that, served as Senior Advisor from 2009 to 2010. Mr. Hassan was Chairman of the Board and Chief Executive Officer of
Schering-Plough Corporation
from 2003 to 2009. Prior to this, Mr. Hassan was Chairman, President and Chief Executive Officer of
Pharmacia Corporation
, from 2001 to 2003. Before assuming these roles, he had served as President and Chief Executive Officer of
Pharmacia Corporation
from its creation in 2000 as a result of the merger of
Pharmacia & Upjohn, Inc.
with
Monsanto Company
. He was President and Chief Executive Officer of
Pharmacia & Upjohn, Inc.
beginning in 1997. Mr. Hassan previously held senior positions with Wyeth (formerly known as American Home Products), including that of Executive Vice President with responsibility for its pharmaceutical and medical products businesses, and served as a member of the board from 1995 to 1997. Prior to that, Mr. Hassan held various roles at
Sandoz Pharmaceuticals
and headed its U.S. pharmaceuticals businesses.
Mr. Hassan has been a director of
Time Warner Inc.
, a media company, since 2009. Mr. Hassan was a director of
Avon Products, Inc.
, a manufacturer and marketer of beauty and related products, from 1999 until 2013 and served as lead independent director from 2009 to 2012 and Chairman of the Board between January and April 2013. Mr. Hassan was Chairman of the Board of Bausch & Lomb, from 2010 until its acquisition by
Valeant Pharmaceuticals International, Inc.
, a pharmaceutical company, in 2013. Mr. Hassan served on the board of directors of
Valeant Pharmaceuticals International, Inc.
between
August 2013
and
May 2014
.
Mr. Hassan's book, "Reinvent - A Leader's Playbook for Serial Success," was published in 2013 by Wiley and describes the linkage between attitude, culture, execution and driven performance. In 2014, a CNBC panel named Mr. Hassan to a list of those who have had the most profound impact on the world of business in the previous quarter century.
Mr. Hassan will serve on the Audit Committee and the Compensation and Management Development Committee of the Board.